K-numberK250680
Device nameBayesian Health Sepsis Flagging Device
ApplicantBayesian Health, Inc.
Product codeSAK
Device classClass II
Decision dateApr 30, 2026
DecisionSubstantially Equivalent
Regulation880.6316
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Bayesian Health Sepsis Flagging Device is an AI/machine learning-based software that continuously monitors patient data from electronic health records to aid healthcare providers in early detection and risk prediction of sepsis developing within 24 hours. It analyzes patient information including comorbidities, lab results, vital signs, medications, and procedures to output a "Sepsis Risk High" flag displayed in the EHR, intended for use in adult patients (≥18 years) in acute care settings as an adjunctive tool alongside clinical assessments.

Technological characteristics

The subject device uses an AI/ML algorithm with 115 patient parameters from EHR data and provides continuous monitoring with flags issued within an hour of new data availability, whereas the predicate uses 22 predetermined inputs and produces a single risk score without continuous monitoring. Both are software-only prescription-use devices designed to identify sepsis risk in adult patients, but the subject device operates independently of blood culture orders and applies to all adult hospitalized patients regardless of suspected sepsis.

Test standards cited

IEC 62304:2006/A1:2015 (medical device software lifecycle processes), IEC 62366-1:2015/A1:2020 (human factors), ANSI AAMI HE75:2009/(R)2018 (human factors), and FDA guidance on cybersecurity, software verification/validation, and human factors engineering.

Substantial equivalence argument

Both devices are Class II AI/ML-based software under 21 CFR 880.6316 intended to aid in sepsis prediction as adjunctive tools for licensed healthcare providers. Despite differences in continuous monitoring capability and independence from blood culture orders, they share the same fundamental intended use, technological approach, and operational principle. Clinical validation on 7,732 encounters demonstrated the device identifies sepsis risk within 24 hours of onset (encounter-level PPA 79.4%, NPA 89.5%), and flag-level performance analysis supports substantial equivalence to the predicate when accounting for the broader patient population served.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →